logo-loader
RNS
Physiomics PLC

Conference Attendance

/**/ sup{font-size:80%}h1{margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;text-align:center;font-size:16.0pt;font-family:"Trebuchet MS","sans-serif";}h3{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Trebuchet MS","sans-serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .ai{size:595.3pt 841.9pt;margin:72.0pt 46.3pt 72.0pt 89.85pt;}div.ai{}p.ba{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";text-align: right}p.bb{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-weight: bold; margin-bottom: 12.1pt; margin-left: 0cm; margin-right: 0cm; margin-top: 12.1pt}span.ax{color:black}p.bc{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-weight: bold; margin-bottom: 0cm; margin-left: 0cm; margin-right: 0cm; margin-top: 12.1pt; text-align: center}p.bd{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-weight: bold; margin-bottom: 0cm; text-align: center}p.be{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-weight: bold; margin-bottom: 0cm; text-align: center; text-autospace: none}p.bf{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-div: italic; margin-bottom: 0cm; text-align: center; text-autospace: none}p.bg{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-autospace: none} p.bh{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;text-autospace:none}p.bi{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify}p.bj{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-weight: bold; margin-bottom: 0cm; text-align: justify}p.bk{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-weight: bold; text-align: justify}p.bl{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-weight: bold; margin-bottom: 0cm; text-align: justify; text-autospace: none}span.am{font-size:10.0pt;color:black}p.bm{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt}p.bn{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-div: italic; font-weight: bold; margin-bottom: 0cm; text-align: justify; text-autospace: none} /**/
RNS Number : 2911M
Physiomics PLC
07 January 2019
 

 

Physiomics plc

("Physiomics") or ("the Company")

 

 

Conference attendance

 

Physiomics to participate in Biotech Showcase partnering conference

 

Physiomics plc (AIM: PYC), is pleased to announce that it will be attending the Biotech Showcase partnering conference in San Francisco from 7-9 January 2019 during the JP Morgan Healthcare Conference week.  During this week, many of the world's most successful biotech and pharmaceutical companies are present in San Francisco to meet with prospective clients and partners.  Over three thousand attendees are expected to participate in over seven thousand organised 1-1 meetings.  Physiomics has confirmed meetings with oncology companies from around the world interested in finding out more about our Virtual Tumour platform and how it can enhance their drug discovery and development programs.

 

 

Enquiries:

 

Physiomics plc                                                  

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

WH Ireland Limited (nomad)

Katy Mitchell

+44 (0) 161 832 2174

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is a solutions provider to the R&D based pharmaceutical and biotechnology industry with a focus on oncology. The Company's Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour has been confirmed by over 60 projects, involving over 25 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

 

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

 

Physiomics senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.

 

For more information please visit:

www.physiomics-plc.com

www.twitter.com/Physiomics

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAQZLFBKFFEBBQ

Quick facts: Physiomics PLC

Price: 2.6

Market: AIM
Market Cap: £1.87 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE